European Parliament votes to adopt the controversial SPC manufacturing waiver

The European Parliament today voted overwhelmingly with 572 Members of Parliament in favor to adopt the Supplementary Protection Certificate (SPC) manufacturing waiver.

The SPC manufacturing waiver is now expected to be formally adopted by the European Council in the coming weeks.

Although the waiver has been largely resisted by the research-based pharma sector, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the parliamentary vote is welcomed by the generics and biosimilars body Medicines for Europe, which today issued a statement commending the EU institutions “for successfully concluding this important step in the adoption of the waiver.”